WBI Investments LLC Takes $3.42 Million Position in Pfizer Inc. (NYSE:PFE)

WBI Investments LLC purchased a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 128,801 shares of the biopharmaceutical company’s stock, valued at approximately $3,417,000. Pfizer makes up about 0.9% of WBI Investments LLC’s portfolio, making the stock its 22nd largest holding.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. St. Clair Advisors LLC purchased a new position in shares of Pfizer during the 4th quarter worth about $954,000. Triglav Skladi D.O.O. bought a new position in shares of Pfizer during the fourth quarter valued at approximately $8,402,000. Twinbeech Capital LP lifted its stake in shares of Pfizer by 303.4% during the 4th quarter. Twinbeech Capital LP now owns 2,318,613 shares of the biopharmaceutical company’s stock worth $61,513,000 after acquiring an additional 1,743,849 shares during the last quarter. Texas Bank & Trust Co purchased a new position in Pfizer during the 4th quarter valued at $944,000. Finally, Tidal Investments LLC grew its position in Pfizer by 41.1% in the 4th quarter. Tidal Investments LLC now owns 268,933 shares of the biopharmaceutical company’s stock valued at $7,135,000 after acquiring an additional 78,305 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $22.83 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business’s 50 day moving average price is $23.65 and its 200 day moving average price is $25.32. The firm has a market cap of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the business posted $0.82 EPS. The company’s revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.54%. Pfizer’s payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on PFE shares. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.